The role of aspirin in women's health

International Journal of Women's Health

Volumn 3, Issue 1, 2011, Pages 151-166

  Verheugt, Freek W A ^a   Bolte, Antoinette C ^b  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; CVD; Menopause; Preeclampsia

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; PROSTAGLANDIN; THROMBOXANE A2;

BRAIN ISCHEMIA; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PREECLAMPSIA; PRIMARY PREVENTION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SIGMOIDOSCOPY; SPONTANEOUS ABORTION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA;

EID: 84055182492     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Jack DB. A hundred years of aspirin. Lancet. 1997;350:437-439.
2. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008;28:s25-s32.
3. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
4. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
5. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-266.
6. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of 5 randomised trials. Lancet. 2010;376:1741-1750.
7. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501-507.
8. Wallenburg HC, Dekker GA, Makovitz J W, et al. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet. 1986;1:1-3.
9. Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791-1798.
10. Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;(2):CD004659.
11. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet. 2001;357:209-215.
12. Shi S, Yamaza T, Akiyama K. Is Aspirin treatment an appropriate intervention to osteoporosis? Fut Rheumatol. 2008;3:499-502.
13. Marshall T. Evaluating national guidelines for prevention of cardiovascular disease in primary care. J Eval Clin Pract. 2005;11:452-461.
14. Becker RC, Meade T W, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(6 Suppl):776S-814S.
15. US Preventive Services Task Force. Aspirin for the prevention of CVD: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396-404.
16. Cannon C P, Rhee KE, Califf RM, et al. Current use of Aspirin and anti-thrombotic agents in the United States among outpatients with atherothrom-botic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010;105:445-452.
17. Berger JS, Brown DL, Burke GL, et al. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable CVD: the Women's Health Initiative Observational Study. Circ Cardiovasc Qual Outcomes. 2009;2:78-87.
18. Enriquez JR, Pratap P, Zbilut J P, et al. Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. Gend Med. 2008;5:53-61.
19. Brennecke S P, Brown MA, Crowther CA, et al. Aspirin and prevention of preeclampsia. Position statement of the use of low-dose aspirin in pregnancy by the Australasian Society for the Study of Hypertension in Pregnancy. Aust N Z J Obstet Gynaecol. 1995;35:38-41.
20. Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010;341:c2207.
21. Société française d'anesthésie et de réanimation (Sfar); Collège national des gynécologues et obstétriciens français (CNGOF); Société française de médecine périnatale (SFMP); Société française de néonatalogie (SFNN). Multidisciplinary management of severe pre-eclampsia (PE). Experts' guidelines 2008. Société française d'anesthésie et de réanimation. Collège national des gynécologues et obstétriciens français. Société française de médecine périnatale. Société française de néonatalogie. Ann Fr Anesth Reanim. 2009;28:275-281. French.
22. Chappell LC, Seed P, Enye S, et al. Clinical and geographical variation in prophylactic and therapeutic treatments for pre-eclampsia in the UK. BJOG. 2010;117:695-700.
23. AHA Women and CVD - Statistics 2010. Available at: http://www.americanheart.org/downloadable/heart/1260905040318FS10WM10.pdf. Accessed June 29, 2010.
24. Mosca L, Mochari-Greenberger H, Dolor RJ, et al. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes. 2010;3:120-127.
25. Verheugt F W, Smith SC. The lady aspirin for cardiovascular disease. Lancet. 2005;366:1148-1150.
26. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of CVD in women. N Engl J Med. 2005;352:1293-1304.
27. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of CVD in women. JAMA. 1991;266: 521-527.
28. Chan AT, Manson JE, Feskanich D, et al. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:5562-5672.
29. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
30. Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology. Clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7:915-926.
31. Kurth T, Bousser M-G. Stroke in women: an evolving topic. Stroke. 2009;40:1027-1028.
32. Patrono C, Coller B, Garret A, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126:234S-264S.
33. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300: 2134-2141.
34. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specifc meta-analysis of randomized controlled trials. JAMA. 2006;295: 306-313.
35. Hillegass WB, Dorfman TA. Aspirin was cost-effective for primary prevention of cardiovascular events in older women at moderate risk. ACP J Club. 2007;147:24.
36. Greving J P, Buskens E, Koffjberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117:2875-2883.
37. Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of CVD in women: a cost-utility analysis. Arch Intern Med. 2007;167:290-295.
38. Algra A, Greving J P. Aspirin in primary prevention: sex and baseline risk matter. Lancet. 2009;373:1821-1822.
39. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 Update: a guideline from the American Heart Association. Circulation. 2011;123:1243-1262.
40. European Stroke Organisation. Guidelines for management of ischemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25: 457-507.
41. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on CVD prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-1610.
42. Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin Thromb Hemost. 2009;35: 295-306.
43. Qayyum R, Becker DM, Yanek LR, et al. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol. 2008;101:1359-1363.
44. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295: 1420-1427.
45. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130-137.
46. World Health Organization 2010. Millennium Development Goals. Available at: http://www.who.int/topics/millennium_development_ goals/maternal_health/en/index.html. Accessed November 17, 2010.
47. Huda SS, Freeman DJ, Nelson SM. Short- and long-term strategies for the management of hypertensive disorders of pregnancy. Expert Rev Cardiovasc Ther. 2009;7:1581-1594.
48. McDonald SD, Malinowski A, Zhou Q, et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156:918-930.
49. Harskamp RE, Zeeman GC. Preeclampsia: at risk for remote cardiovascular disease. AM J Med Sci. 2007;334:291-295.
50. McDonald SD, Han Z, Walsh M W, et al. Kidney disease after preec-lampsia: a systematic review and meta-analysis. Am J Kidney Dis. 2010; 55:1026-1039.
51. Xu XF, Du LZ. Epigenetics in neonatal diseases. Chin Med J (Engl). 2010;123:2948-2954.
52. Kajantie E, Eriksson JG, Osmond C, et al. Pre-eclampsia is associated with increased risk of stroke in the adult offspring. The Helsinki Birth Cohort Study. Stroke. 2009;40:1176-1180.
53. Geelhoed JJ, Jaddoe V W. Early influences on cardiovascular and renal development. Eur J Epidemiol. 2010;25:677-692.
54. Crispi F, Comas M, Hernández-Andrade E, et al. Does pre-eclampsia influence fetal cardiovascular function in early-onset intrauter-ine growth restriction? Ultrasound Obstet Gynecol. 2009;34: 660-665.
55. Leduc L, Dubois E, Takser L, et al. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007;29:787-793.
56. Bujold E, Morency AM, Roberge S, et al. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2009;31: 818-826.
57. Lambers MJ, Groeneveld E, Hoozemans DA, et al. Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. Hum Reprod. 2009;24:2447-2450.
58. Urban G, Vergani P, Tironi R, et al. Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy. Int J Fertil Womens Med. 2007;52: 59-67.
59. Ruano R, Fontes RS, Zugaib M. Prevention of preeclampsia with low-dose aspirin - a systematic review and meta-analysis of the main randomized controlled trials. Clinics (Sao Paulo). 2005;60: 407-414.
60. Ebrashy A, Ibrahim M, Marzook A, et al. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J. 2005;46:826-831.
61. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy. Obstet Gynecol. 2010;116:402-414.
62. August P, Helseth G, Edersheim T, et al. Sustained release, low-dose aspirin ameliorates but does not prevent preeclampsia (PE) in a high risk population. Proceedings of the 9th International Congress, International Society for the Study of Hypertension. March 15-18, 1994, Sydney, Australia. Hypertension in Pregnancy. p. 72.
63. Azar R, Turpin D. Effect of antiplatelet therapy in women at high risk for pregnancy-induced hypertension. Proceedings of 7th World Congress of Hypertension in Pregnancy. October 1990, Perugia, Italy. p. 257.
64. Beaufls M, Uzan S, Donsimoni R, et al. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985;1:840-842.
65. Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med. 1989;321:357-362.
66. Hermida RC, Ayala DE, Iglesias M, et al. Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. Hypertension. 1997;30:589-595.
67. Michael CA, Walters BNJ. Low-dose aspirin in the prevention of pre-eclampsia: current evaluation. In: Teoh ES, Ratnam SS, Macnaughton MC, eds. Maternal physiology and pathology. The current status of gynaecology and obstetrics series. Carnforth, UK: Parthenon Publishing Group Ltd; 1992. p.183-189.
68. Tulppala M, Marttunen M, Soderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod. 1997;12:1567-1572.
69. Vainio M, Kujansuu E, Iso-Mustajarvi M, et al. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. Br J Obstet Gynecol. 2002;109:161-167.
70. Dasari R, Narang A, Vasishta K, et al. Effect of maternal low dose aspirin on neonatal platelet function. Indian Pediatr. 1998;35:507-511.
71. Hermida RC, Ayala DE, Fernandez JR, et al. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension. 1999;34:1016-1023.
72. Coomarasamy A, Honest H, Papaioannou S, et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003;101:1319-1332.
73. Hermida RC, Ayala DE, Iglesias M. Administration time-dependence influence of aspirin on blood pressure in pregnant women. Hypertension. 2003;41(3 Pt 2):651-656.
74. Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis. 2008;2:249-259.
75. Hertig A, Watnick S, Stevens H, et al. How should women with pre-eclampsia be followed up? New insights from mechanistic studies. Nat Clin Pract Nephrol. 2008;4:503-509.
76. Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess. 2008;12:3-4,1-270.
77. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376:1498-1509.
78. Mak A, Cheung M W, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford). 2010;49:281-288.
79. Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus. 2010;19: 58-64.
80. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphos-pholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115:1256-1262.
81. Cohn DM, Goddijn M, Middeldorp S, et al. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost. 2010;8:2208-2213.
82. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol. 2009;36: 279-287.
83. Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet. 2009; 104:223-225.
84. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit. 2006;12:CR132-CR136.
85. Empson M, Lassere M, Craig J, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;(18):CD002859.
86. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl):627S-644S.
87. Flood K, Peace A, Kent E, et al. Platelet reactivity and pregnancy loss. Am J Obstet Gynecol. 2010;203(281):e1-e5.
88. Kaandorp S, Di Nislo M, Goddijn M, et al. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev. 2009;CD004734.
89. McCarty DJ, Manzi S, Medsger TA, et al. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 1995;38:1260-1270.
90. Haque S, Bruce IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2005;2:423-430.
91. Costenbader KH, Karlson EW, Gall V, et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum. 2005;53:718-723.
92. Markowitz SD. Aspirin and colon cancer-targeting prevention? N Engl J Med. 2007;356:2195-2198.
93. Schrör K. Acetylsalicylic Acid. Weinheim, Germany: Wiley-Blackwell; 2009.
94. American Cancer Society: Cancer Facts and Figures 2010. Atlanta, Ga: American Cancer Society; 2010. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113. pdf. Accessed November 15, 2010.
95. Wei EK, Colditz GA, Giovannucci EL, et al. Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses' Health Study. Am J Epidemiol. 2009;170:863-872.
96. Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28:1467-1472.
97. Bardia A, Olson JE, Vachon CM, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011;126:149-155.
98. McTiernan A, Wang CY, Sorensen B, et al. No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev. 2009;18:1524-1530.
99. Zhao YS, Zhu S, Li X W, et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat. 2009;117:141-150.
100. Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 2008;100:1439-1447.
101. Zhang SM, Cook NR, Manson JE, et al. Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer. 2008;98:989-991.
102. Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf. 2008;17:115-124.
103. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized trial. JAMA. 2005;294:47-55.
104. Viswanathan AN, Feskanich D, Schernhammer ES, et al. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res. 2008;68:2507-2513.